Intranasal administration of glucose-regulating peptides

Details Intranasal administration of glucose-regulating peptides Intranasal administration of glucose-regulating peptides

A - Human Necessities

61

K

A61K 38/22 (2006.01) A61K 9/00 (2006.01) A61K 38/17 (2006.01) A61K 38/26 (2006.01) A61K 47/06 (2006.01)

Patent

CA 2551530

Pharmaceutical compositions and methods are described comprising at least one glucose-regulating peptide, such as amylin, glucagon-like peptide-1 (GLP), pramlintide or exendin-4 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the amylin, for treating a variety of diseases and conditions in mammalian subjects, including obesity and diabetes mellitus.

L'invention porte sur des procédés et sur des compositions pharmaceutiques comprenant au moins un peptide régulant le glucose, tel que l'amyline, un peptide-1 de type glucagon (GLP), pramlintide ou exendin-4 et au moins un ou plusieurs agents améliorant l'administration par les muqueuses nasales et destinés à l'administration de l'amyline en vue de traiter diverses maladies et états chez des sujets mammaliens tels que l'obésité et le diabète sucré.

Affiliated with

Also associated with

Rating

Intranasal administration of glucose-regulating peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Intranasal administration of glucose-regulating peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intranasal administration of glucose-regulating peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1345043